6533b820fe1ef96bd1279a89
RESEARCH PRODUCT
Ustekinumab therapy changes the transcriptional activity pattern of TGF-β1–3 genes
Dominika Wcisło-dziadeckaAndrzej PlewkaBarbara Strzalka-mrozikBeniamin GrabarekJoanna Golasubject
molecular markerMessenger RNAOriginal Paperbusiness.industrymedicine.medical_treatmentRNApsoriasis arthritisDermatologyPharmacologymedicine.diseasePeripheral blood mononuclear cellRC31-1245ustekinumabPsoriatic arthritisCytokineRL1-803UstekinumabmedicineImmunology and Allergytgfβ1-3businessGeneInternal medicinemedicine.drugTransforming growth factordescription
Introduction One of the examples of genes whose expression can be altered by the action of ustekinumab is TGF-β. It is a pleiotropic cytokine whose activity affects psoriatic changes and the state of homeostasis of the whole organism. Aim To evaluate the effect of ustekinumab on the transcriptional activity of TGF-b family genes in patients with psoriatic arthritis and to check whether the results obtained can be helpful in monitoring the progress of treatment. Material and methods From total PBMCs obtained from peripheral blood of 14 patients with psoriatic arthritis, total RNA was isolated. The expression level of the TGF-β1, TGF-β2 and TGF-β3 genes was determined by RT-qPCR in real time. Results In all the analysed samples, the presence of mRNA of three TGF-β isoforms was quantitated in each week of therapy. TGF-β3 and the smallest TGF-β2 showed the highest expression. Statistically significant correlations were observed in the amount of TGF-β1 and TGF-β3/µg mRNA RNA, TGF-β2 and TGF-β2/µg RNA and TGF-β3 and TGF-β3/µg RNA. Conclusions Ustekinumab influences the transcriptional activity of TGF-β genes, and the changes caused have a bearing on the patient’s health.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2019-09-29 | Advances in Dermatology and Allergology |